California State Teachers Retirement System decreased its position in shares of TESARO Inc (NASDAQ:TSRO) by 9.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 61,747 shares of the biopharmaceutical company’s stock after selling 6,343 shares during the quarter. California State Teachers Retirement System owned approximately 0.11% of TESARO worth $7,972,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after purchasing an additional 195,590 shares during the period. Vanguard Group Inc. boosted its stake in TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after purchasing an additional 62,104 shares during the period. State Street Corp boosted its stake in TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after purchasing an additional 177,057 shares during the period. BB Biotech AG boosted its stake in TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after purchasing an additional 53,408 shares during the period. Finally, Janus Henderson Group PLC bought a new position in TESARO in the 2nd quarter worth about $100,301,000.
TESARO Inc (NASDAQ:TSRO) opened at $82.85 on Thursday. The firm has a market capitalization of $4,387.53, a PE ratio of -9.82 and a beta of 1.52. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO Inc has a 1-year low of $76.13 and a 1-year high of $192.94.
Several research analysts have commented on the company. Citigroup restated a “buy” rating and issued a $135.00 target price (down previously from $216.00) on shares of TESARO in a research note on Wednesday, December 20th. Robert W. Baird restated a “neutral” rating and issued a $125.00 target price on shares of TESARO in a research note on Monday, October 2nd. Jefferies Group restated a “hold” rating and issued a $124.00 target price on shares of TESARO in a research note on Friday, November 3rd. Oppenheimer restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Sunday, September 10th. Finally, Royal Bank of Canada assumed coverage on TESARO in a report on Thursday, September 14th. They issued a “sector perform” rating and a $120.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO currently has an average rating of “Buy” and an average target price of $156.01.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 34.60% of the company’s stock.
WARNING: “California State Teachers Retirement System Cuts Stake in TESARO Inc (TSRO)” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/28/california-state-teachers-retirement-system-cuts-stake-in-tesaro-inc-tsro.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
What are top analysts saying about TESARO? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO and related companies.